Bronchitis Treatments

Find Bronchitis Treatments

For anyone who has experienced bronchitis, the sensation is unmistakable: a deep, rattling cough that seems to linger for weeks, often accompanied by chest tightness and profound fatigue. Whether it is a short-term bout following a cold or a chronic condition requiring ongoing management, bronchitis disrupts sleep, work, and daily energy levels. The persistent coughing can leave muscles sore and make simple tasks feel exhausting.

Treatment is essential to relieve this discomfort, help clear mucus from the airways, and allow the body to rest and recover. While acute bronchitis often improves on its own with time, managing the symptoms makes the recovery process much more bearable. It is critical to distinguish between acute bronchitis (usually temporary and viral) and chronic bronchitis (a long-term condition often linked to smoking or environmental irritants). Medication plans vary significantly between these two types, depending on whether the goal is short-term symptom relief or long-term disease management (National Heart, Lung, and Blood Institute, 2022).

Overview of treatment options for Bronchitis

The approach to treating bronchitis depends entirely on whether the condition is acute or chronic. For acute bronchitis, which is almost always caused by a virus, the primary goal is supportive care, managing the cough, fever, and pain while the immune system fights the infection. Medications here target symptoms, not the underlying virus.

For chronic bronchitis, which is a form of chronic obstructive pulmonary disease (COPD), the goal is to reduce inflammation, open the airways, and prevent flare-ups. This requires a more complex, often daily, medication regimen. In both cases, lifestyle measures like hydration and avoiding smoke are foundational, but pharmacological treatments provide the necessary relief to function. Clinical experience suggests that antibiotics are frequently requested but rarely necessary for acute cases, as they do not kill viruses.

Medications used for Bronchitis

For acute bronchitis, over-the-counter medications are the first line of defense. Expectorants, such as guaifenesin, are commonly used to thin mucus, making it easier to cough up. Conversely, cough suppressants like dextromethorphan help block the cough reflex to allow for sleep, though doctors often recommend letting a “productive” cough do its job during the day. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or aspirin, as well as acetaminophen, are used to lower fever and relieve chest soreness.

If wheezing or difficulty breathing is present, doctors may prescribe a short-acting bronchodilator. Albuterol is a well-known example in this class, used temporarily to open the airways.

For chronic bronchitis, treatment is more aggressive. Long-acting bronchodilators (both beta-agonists and anticholinergics) are used daily to keep airways open. Inhaled corticosteroids, such as fluticasone or budesonide, are often added to reduce chronic inflammation in the bronchial tubes. In severe cases, phosphodiesterase-4 inhibitors like roflumilast may be prescribed to decrease flare-ups.

Antibiotics, such as azithromycin or doxycycline, are generally reserved for cases where there is a confirmed bacterial infection or for patients with chronic lung conditions experiencing a severe exacerbation (Centers for Disease Control and Prevention, 2021).

How these medications work

Expectorants work by increasing the water content of the mucus, thinning it out so it moves more easily through the airways. Suppressants act on the part of the brain that controls the coughing reflex, essentially “muting” the urge to cough.

Bronchodilators relax the smooth muscles wrapped around the airways. When these muscles tighten (bronchospasm), breathing becomes hard. These drugs release that tension, widening the tubes to let more air pass through. Corticosteroids work by suppressing the immune system’s inflammatory response, reducing the swelling and mucus production inside the bronchial tubes that characterize chronic bronchitis (Mayo Clinic, 2023).

Side effects and safety considerations

Cough/cold medicines can cause drowsiness/dizziness. Expectorants are safe but require ample water to be effective. Bronchodilators, like albuterol, may cause temporary increased heart rate, jitteriness, or shaking hands.

Inhaled corticosteroids can cause oral thrush if the mouth isn’t rinsed afterward. Long-term use of oral steroids/strong anti-inflammatories risks stomach/bone issues. Avoid unnecessary antibiotics, as overuse causes resistance and digestive problems. Seek immediate care for unresolving shortness of breath, high fever, or blood in mucus. Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. Centers for Disease Control and Prevention. https://www.cdc.gov
  2. Mayo Clinic. https://www.mayoclinic.org
  3. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov
  4. American Lung Association. https://www.lung.org

Medications for Bronchitis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Bronchitis.

Found 14 Approved Drugs for Bronchitis

Azithromycin

Brand Names
Azasite, Zithromax

Azithromycin

Brand Names
Azasite, Zithromax
Azithromycin for oral suspension USP is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications.

Trimethoprim

Brand Names
Sulfamethox-TMP, Sulfatrim, Sulfamethoxazole, Bactrim, Sulfameth

Trimethoprim

Brand Names
Sulfamethox-TMP, Sulfatrim, Sulfamethoxazole, Bactrim, Sulfameth
Urinary Tract Infections Sulfamethoxazole and Trimethoprim Injection is indicated in the treatment of severe or complicated urinary tract infections in adults and pediatric patients two months of age and older due to susceptible strains of Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris when oral administration of Sulfamethoxazole and Trimethoprim Injection is not feasible and when the organism is not susceptible to single-agent antibacterials effective in the urinary tract. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Injection and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Although appropriate culture and susceptibility studies should be performed, therapy may be started while awaiting the results of these studies. Shigellosis Sulfamethoxazole and Trimethoprim Injection is indicated in the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei in adults and pediatric patients two months of age and older. Sulfamethoxazole and Trimethoprim Injection is a combination of sulfamethoxazole, a sulfonamide antimicrobial, and trimethoprim, a dihydrofolate reductase inhibitor antibacterial, indicated in adults and pediatric patients two months of age and older for treatment of infections caused by designated, susceptible bacteria. Pneumocystis jirovecii Pneumonia. Pneumocystis jirovecii Pneumonia Sulfamethoxazole and Trimethoprim Injection is indicated in the treatment of Pneumocystis jirovecii pneumonia in adults and pediatric patients two months of age and older.

Clarithromycin

Generic Name
Clarithromycin

Clarithromycin

Generic Name
Clarithromycin
Clarithromycin is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults.

Ofloxacin

Brand Names
Ocuflox, Ofloxacin Ophth, Olfoxacin

Ofloxacin

Brand Names
Ocuflox, Ofloxacin Ophth, Olfoxacin
OCUFLOX ® ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species: Propionibacterium acnes.

Moxifloxacin

Brand Names
Strenza, Vigamox

Moxifloxacin

Brand Names
Strenza, Vigamox
Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species * Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenzae Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. Moxifloxacin ophthalmic solution is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri*, Streptococcus pneumoniae, Streptococcus viridans group, Acinetobacter lwoffii*, Haemophilus influenzae, Haemophilus parainfluenzae*, Chlamydia trachomatis. *Efficacy for this organism was studied in fewer than 10 infections.
Showing 1-5 of 14
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances